drugset / Trial / NCT06180863
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
Phase 2
Withdrawn
Yale University
Bristol-Myers Squibb · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
To investigate the feasibility of delivering oral azacitidine (CC-486) as a consolidation regimen from the time of first complete remission (CR1), in patients with acute myelogenous leukemia (AML) eligible for curative intent Allogeneic Stem Cell Transplant (ASCT).
Timeline
- Start
- 2023-11
- Primary completion
- 2028-11
- Completion
- 2029-04
Outcome
Outcome not reported
Stopped (Business): “Lack of funding.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 200 mg | Oral |
| Subject | Azacitidine | Other / unclassified | 300 mg | Oral |